Avicanna Inc. (0NN.F)

0.2320 -0.0040 (-1.69%) At close: 08:52AM CEST

Avicanna Inc.

480 University Avenue
Suite 1502
Toronto, ON M5G 1V2
Canada

https://www.avicanna.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 87

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Aras Azadian B.Econ, Mba	Co-Founder, CEO & Director	109.03k	N/A	N/A
Mr. Phillip Cardella C.A., CPA	Chief Financial Officer	96.78k	N/A	N/A
Dr. Frantz Le Devedec	Executive Vice President of Research & Development	89.49k	N/A	N/A
Mr. Stephen Kim	Chief Legal Officer & General Counsel of Avicanna USA Inc.	139.07k	N/A	N/A
Mr. Arash Moghani MBA	Executive Vice President of Operations & Technology	N/A	N/A	N/A
Ms. Ingrid Diaz	VP, Assistant General Counsel & Corporate Compliance Officer	N/A	N/A	N/A
Ms. Ivana Maric	Executive Vice President of Marketing	N/A	N/A	N/A
Mr. Enric Pujol	Vice President of People	N/A	N/A	N/A
Dr. Carlos Enrique Maldonado Muete	SVP of Clinical Development	N/A	N/A	N/A
Dr. Karolina Urban	Executive Vice President of Scientific & Medical Affairs	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. It also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, the company operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, and educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens, as well as collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Corporate Governance

Avicanna Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.